Nonpeptide Arginine Vasopressin Antagonists for Both V1A and V2 Receptors: Synthesis and Pharmacological Properties of 2-Phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl)benzanilide Derivatives.
A series of compounds structurally related to 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide was synthesized and demonstrated to have arginine vasopressin (AVP) antagonist activity for both V1A and V2 receptors. The introduction of a hydrophilic substituent group into the 5-position of the benzodiazepine ring resulted in an increase in oral availability. Especially, the
Branched poly(ionic liquid)-modified magnetic nanoparticles as a nitrogen-rich and hydrophilic support for stabilization of Pd nanoparticles and exploring its catalytic activity
作者:Mohammad Gholinejad、Fatemeh Zareh、Hossein Bagheri、Nasser Nikfarjam、José M. Sansano
DOI:10.1007/s11164-024-05268-8
日期:2024.6
magnetometry, thermogravimetric analysis and energy-dispersive X-ray. The synthesized catalyst has been applied as an efficient catalyst in the reduction of nitrocompounds to corresponding amines and reductive degradation of organic dyes such as methyl orange and methyl red. The catalyst showed high stability and reusability for 10 runs without significant loss in catalytic activity. Graphical abstract
Goldfarb I. J., Feld W. A., Prijaya H., Bhat S. S., Polym. Prepr./Amer. Chem. Soc, 35 (1994) N 2, S 682-683
作者:Goldfarb I. J., Feld W. A., Prijaya H., Bhat S. S.
DOI:——
日期:——
KORSHAK V. V.; PYCAHOB A. L.; BATIROV I.; KALONTAROV I. YA.; NIYAZI F. F.+, DOKL. AN TADZH. CCP, 1977, 20, HO 8, 34-39
作者:KORSHAK V. V.、 PYCAHOB A. L.、 BATIROV I.、 KALONTAROV I. YA.、 NIYAZI F. F.+
DOI:——
日期:——
SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES
申请人:Winfield Leyte L.
公开号:US20120095009A1
公开(公告)日:2012-04-19
This invention provides for compounds, compositions, and methods that involve anti-proliferative and anti-neoplastic activity in cancer cells. In particular, a series of benzimidazole, purine, imidazopyridine, and imidazopyrizine compounds having selected substitution patterns are disclosed, and the activity of various subject compounds is demonstrated. In particular, the disclosure provides for substituted imidazo[4,5-b]pyrazine compounds having the general formula
their salts, pharmaceutical compositions, and methods of treatment using the subject compounds and compositions.